Neurodevelopment Clinical Trial
— IFOOfficial title:
Individualized Fortification of Breast Milk With Fat, Carbohydrate and Protein for Preterm Infants
NCT number | NCT01609894 |
Other study ID # | 201205IFO |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | May 30, 2012 |
Last updated | August 10, 2016 |
Start date | August 2013 |
The proposed research will investigate individualized fortification of breast milk based on
daily milk analysis of carbohydrate, protein, and fat content in a randomized double blind
controlled trial. The combination of additional fat, carbohydrate and protein and commercial
fortifier will be added to ensure that the milk contains the target amounts of nutrient.
Growth and development of these infants will be compared with that of infants fed mother's
milk that has been supplemented with the current standard amounts. The postnatal growth of
the infants will be assessed by measuring weight, length and head circumference and fat and
lean mass using highly accurate, non-invasive methods throughout the intervention period and
at the first follow-up visit after discharge at 3 months. Neurological development will be
analyzed at the age of 18 months.
The investigators hypothesize that individualized fortification of breast milk improves the
nutritional intake of preterm infants, optimizing growth, and thus this will positively
impact neurodevelopment and health.
Status | Recruiting |
Enrollment | 112 |
Est. completion date | |
Est. primary completion date | June 2018 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A to 32 Weeks |
Eligibility |
Inclusion criteria: 1. Gestational age < 32weeks (maternal dates or early fetal ultrasound); 2. Tolerating an enteral intake of = 100 ml/kg/d for = 24h; 3. Subject is anticipated to receive the intervention for = 3 consecutive weeks after full enteral feeding (= 150 mL/kg/d) has been achieved; and 4. Written informed consent has been obtained from the infant's legal representative. Exclusion criteria: 1. Infants with intrauterine growth restriction, small for gestational age defined by a weight less than 3rd percentile using sex specific reference data for birth weight 2. Gastrointestinal malformation, major congenital anomalies and chromosomal abnormalities; 3. Babies with enterostoma or short gut syndrome; 4. Necrotizing enterocolitis, defined by feeding intolerance associated with positive x-ray findings (pneumatosis intestinalis - Bell Stage 2; air in the biliary tract or free air in the peritoneum - Bell Stage 3); 5. Renal disease, defined by symptoms (oliguria, anuria, proteinuria, hematuria) associated with an increased blood urea nitrogen 10 mmol/L79 and creatinine of 130 mmol/L80; 6. Hepatic dysfunction, defined by jaundice (direct bilirubin >1.0 mg/dl) that is associated with one or more abnormal liver function tests (AST, ALT or GGT); 7. Participation in another clinical trial that may affect outcomes of this study; or 8. Probability of transfer to another NICU or level II nursery outside the McMaster Children's Hospital before the minimum period of three weeks is completed. Post-randomisation exclusion criteria: 1. Infants fed more than 25% of mean caloric intake for a consecutive week with formula milk; 2. Fluid restriction < 140mL/kg/d for = 3 consecutive days; 3. Sepsis - all infants with gram-negative sepsis will be removed from the study. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Faculty of Health Science, McMaster Children's Hospital | Hamilton | Ontario |
Lead Sponsor | Collaborator |
---|---|
McMaster Children's Hospital |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | growth during first three weeks of intervention | change in body weight gain will be accessed daily. | first three weeks during intervention before 36 weeks of gestation | No |
Secondary | enteral energy intake | fat, carbohydrate, protein, and caloric intake by enteral feeding will be assesed daily | from inclusion at postmentrual age <32 weeks until 36 weeks | No |
Secondary | neurodevelopment | Bayley Scales of Infant Development III | at 18 month corrected age | No |
Secondary | weight gain | change in body weight [g] | from inclusion at postmentrual age <32 weeks until 18 month corrected age | No |
Secondary | body length | change in body length [cm] | from inclusion at postmentrual age <32 weeks until 18 month corrected age | No |
Secondary | head circumference | change in head circumference [cm] | from inclusion at postmentrual age <32 weeks until 18 month corrected age | No |
Secondary | body composition | change in body composition measured with air displacement plethysmography (body weight, body volume, calculated fat and lean mass) | from inclusion at postmentrual age <32 weeks until 3 month corrected age | No |
Secondary | body composition (bio-electrical impedance analysis) | change in body composition measured with bio-electrical impedance analysis (impedance at 5, 50, 100 and 200 kHz, resistance at 50 kHz, reactance at 50 kHz, phase angle at 50 kHz) | from inclusion at postmentrual age <32 weeks until 18 month corrected age | No |
Secondary | skin fold thickness | change in skin fold thickness [cm] | from inclusion at postmentrual age <32 weeks until 18 month corrected age | No |
Secondary | feeding intolerance | occurence of feeding intolerance defined by vomitting, bloody gastric residuals, or abnormal abdomen (tender, discolored, absent bowel sounds) | during intervention (postmentrual age <32 weeks until 36 weeks) | No |
Secondary | morbidity | during intervention (postmentrual age <32 weeks until 36 weeks) | No | |
Secondary | nutrient's blood parameter | triglycerides, glucose, blood urea nitrogen, blood gases, electrolytes, pH | during intervention (postmentrual age <32 weeks until 36 weeks) | No |
Secondary | breast milk analysis | using near-infrared analysis breast milk's macronutrients (fat, lactose and protein) will be measured daily | during intervention (postmentrual age <32 weeks until 36 weeks) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02184780 -
Impact of Perinatal Anaesthesia and Analgesia on Neurocognitive Outcomes in Early Childhood
|
||
Completed |
NCT03420872 -
Nutrient Mixtures and Neurodevelopment
|
||
Not yet recruiting |
NCT06429007 -
A Safety and Feasibility Trial Protocol of Metformin in Infants After Perinatal Brain Injury
|
Phase 2 | |
Completed |
NCT02208960 -
Newborn Kit to Save Lives and Brains in Kenya
|
Phase 3 | |
Recruiting |
NCT03633162 -
Maternal Grandmothers in the Born in Guangzhou Cohort Study
|
||
Recruiting |
NCT04137445 -
The Effects of Early Complementary Feeding on Growth, Neurodevelopment, Sleep and Gut Health
|
N/A | |
Completed |
NCT02759263 -
Improving Neurodevelopment in Adolescents With Congenital Heart Disease
|
N/A | |
Recruiting |
NCT04593095 -
Nurturing and Quiet Intervention: NeuroN-QI
|
N/A | |
Withdrawn |
NCT05045092 -
A Follow-up Study of Neonates Receiving Extracorporeal Life Support in China
|
||
Recruiting |
NCT03629093 -
Neurodevelopment of Infants Exposed to General Anesthesia: a Multi-center Investigation
|
||
Recruiting |
NCT03331133 -
Twins Born in Guangzhou
|
||
Recruiting |
NCT03668327 -
Preterm Birth Cohort Study in Guangzhou
|
||
Recruiting |
NCT02526901 -
The Born in Guangzhou Cohort Study (BIGCS)
|
||
Recruiting |
NCT03650829 -
IVF Offspring Born in Guangzhou
|
||
Recruiting |
NCT04529889 -
GDM and Its Consequences in Mothers and Offsprings
|
||
Completed |
NCT02610959 -
Iodine Status During Pregnancy and Its Effect on Infant Development.
|
N/A | |
Not yet recruiting |
NCT05977400 -
NICU Antibiotics and Outcomes (NANO) Follow-up Study
|
Phase 3 |